Univest
Univest
  • Markets

Medanta Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review

  • June 11, 2026
  • Posted by: Neeraj Pandey
  • Category: News
No Comments
Medanta Stock Prediction

Medanta CMP: Rs 1,230.5 (2026). 52W High: Rs 1,456. 52W Low: Rs 955. Mkt Cap: Rs 33,007 Cr. P/E: 66.5. Analyst Consensus: Rs 1425.

The Medanta stock prediction for 2026 from leading brokerages covers a range reflecting sector dynamics, earnings trajectory and the macro environment. All estimates may or may not be achieved. Treat any Medanta share price prediction as one data point and not as a guarantee of future performance.

This article reviews every dimension of the Medanta stock forecast analysts are tracking, including key drivers, bull and bear scenarios and the primary risks. Verify all figures with the latest brokerage reports before any investment decision.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Analysts Predict for Medanta Stock in 2026
  • Medanta Company Overview
  • Medanta Stock Prediction by Time Horizon
    • Short-Term Medanta Stock Prediction
    • 12-Month Medanta Stock Prediction
    • Long-Term Medanta Stock Prediction
  • Medanta Stock Forecast: Key Factors
    • Bed Addition and Occupancy
    • Revenue per Occupied Bed
    • EBITDA Margin Maturity
    • International Patient Revenue
  • Medanta Stock Prediction: Bull and Bear Scenarios
  • How Analysts Are Reading the Medanta Stock Story
  • Key Risks to the Medanta Stock Prediction
    • New Hospital Ramp-Up Costs
    • Regulatory and Price Cap Risk
    • Competition
    • Medical Cost Inflation
  • How to Monitor the Medanta Stock Forecast
  • Conclusion
  • Frequently Asked Questions on Medanta Stock Prediction 2026
    • What is the Medanta stock prediction for 2026?
    • Is the Medanta stock prediction bullish or bearish?
    • What is the Medanta share price prediction based on fundamentals?
    • What is the long-term Medanta stock prediction?
    • What are the key risks to the Medanta stock prediction?
    • What does the Medanta stock forecast say for 2026?
    • Where can I track the latest Medanta stock prediction?

What Analysts Predict for Medanta Stock in 2026

Analyst consensus on the Medanta stock prediction for 2026 is tracked by leading brokerages. The table below shows the latest available data from JM Financial and ICICI Securities. All figures are sourced from publicly available research and should be verified before publishing.

Brokerage Rating Medanta Stock Prediction (Rs) Updated
JM Financial Buy Rs 1450 2026
ICICI Securities Buy Rs 1400 2026
Analyst Consensus — Rs 1425 2026

The Medanta stock prediction range reflects genuine difference of opinion on demand recovery, margin trajectory and sector headwinds. The implied upside in the Medanta stock forecast from the current price of Rs 1,230.5 may or may not be realised by end of 2026.

3 Stocks Building Serious Momentum Right Now

When Univest analysts identify high-conviction stock opportunities, investors pay attention.

Our research team has shortlisted the Top Stocks to Buy based on current market momentum, sector trends & growth potential for 2026.

  • Discover stocks investors are actively accumulating
  • High-conviction opportunities backed by research
  • Designed for the next phase of market growth

Unlock the latest Top Stock Picks now on Univest

See the Stocks →

Medanta Company Overview

Global Health is a leading healthcare services provider operating hospitals, diagnostics or specialty facilities across India. The Medanta stock prediction for 2026 reflects structural growth in healthcare demand and operating leverage from bed expansion.

Metric Value
NSE Ticker MEDANTA
Sector Healthcare Services and Hospitals
CMP Rs 1,230.5 (2026)
52 Week High Rs 1,456
52 Week Low Rs 955
Market Cap Rs 33,007 Cr
P/E Ratio 66.5
Medanta Stock Prediction Consensus (12M) Rs 1425

Medanta Stock Prediction by Time Horizon

Analysts split the Medanta share price prediction across time frames as near-term drivers differ materially from the long-term view.

Short-Term Medanta Stock Prediction

The near-term Medanta stock forecast reflects current sentiment, sector news and upcoming earnings prints. Key support and resistance levels around Rs 1,230.5 are being watched closely. A short-term Medanta share price prediction carries the most uncertainty of any time horizon.

12-Month Medanta Stock Prediction

JM Financial targets Rs 1450 (Buy) and ICICI Securities targets Rs 1400 (Buy). Most desks refresh their Medanta stock forecast within two to four weeks of each quarterly earnings print. The Medanta share price prediction should be verified against the most recent analyst reports.

Long-Term Medanta Stock Prediction

The long-term Medanta stock prediction is built on assumptions about demand recovery, margin expansion and revenue diversification in the Healthcare Services and Hospitals sector. The long-term Medanta share price prediction carries the most uncertainty and should be treated as directional guidance only.

Medanta Stock Forecast: Key Factors

The following four factors appear consistently in research reports on the Medanta stock prediction and are the primary inputs into the bull and bear case scenarios.

Bed Addition and Occupancy

Hospital bed additions and occupancy rates are the primary metrics in the Medanta stock forecast. Analysts look for occupancy above 65 percent as the basis for a higher Medanta share price prediction.

Revenue per Occupied Bed

Revenue per occupied bed improvement reflects the shift to higher-margin specialties. Analysts revise the Medanta share price prediction upward when per-bed revenue grows consistently.

EBITDA Margin Maturity

A portfolio shift toward mature hospitals supports the bullish Medanta stock prediction, while new hospital ramp-ups dilute margins in the near term.

International Patient Revenue

Medical tourism revenue provides premium pricing and diversifies the revenue base, supporting the Medanta stock forecast and premium valuation.

Medanta Stock Prediction: Bull and Bear Scenarios

Scenario Medanta Stock Prediction Key Conditions
Bull Case Rs 1450 Strong execution, margin improvement, favourable macro and sector re-rating
Base Case Rs 1425 Steady performance, gradual recovery, margins hold, growth on track
Bear Case Rs 955 Demand deterioration, margin pressure, sector de-rating and macro headwinds

The bull case Medanta stock forecast of Rs 1450 assumes most positive variables converge. The base case of Rs 1425 is the analyst consensus and may or may not be achieved.

How Analysts Are Reading the Medanta Stock Story

Analyst reviews of the Medanta share price prediction highlight the company’s core strengths in Healthcare Services and Hospitals alongside near-term headwinds from macro uncertainty, competitive pressure and sector-level challenges. Overall the Medanta stock prediction consensus is built on real business strengths set against real risks.

Key Risks to the Medanta Stock Prediction

New Hospital Ramp-Up Costs

New hospital investments have multi-year ramp-up periods during which margins are diluted. This is a recurring near-term risk to the Medanta stock prediction.

Regulatory and Price Cap Risk

Government-mandated price caps on medical procedures affect hospital revenues and can compress the Medanta stock forecast.

Competition

New hospital chains expanding into metro and tier 2 cities create competitive pressure on occupancy and billing, which is a recurring caution in the Medanta share price prediction.

Medical Cost Inflation

Rising manpower and consumables costs affect EBITDA margins and the Medanta stock forecast. Cost risk is reflected in the width of the Medanta share price prediction range.

How to Monitor the Medanta Stock Forecast

Track the Medanta share price prediction consensus quarterly. After every earnings release, most brokerages revise their Medanta stock forecast within two weeks. Comparing the revised Medanta stock prediction to the previous estimate tells you whether analyst sentiment is improving or deteriorating.

Compare the current price of Rs 1,230.5 with the analyst target range of Rs 1450 to Rs 1400. A wide Medanta stock prediction band reflects genuine uncertainty, so position size should reflect that range rather than the midpoint alone.

Review the Medanta share price prediction every quarter against key business metrics for the Healthcare Services and Hospitals sector. A single estimate from any analyst is a point-in-time view and should be treated as one input among many when making any investment decision.

Check Live Medanta Fundamentals on the Univest Screener

Conclusion

The Medanta stock prediction for 2026 reflects the analyst community’s assessment of Global Health’s competitive position, earnings trajectory and macro environment. JM Financial holds a Buy stance with a target of Rs 1450 while ICICI Securities has a Buy rating with a target of Rs 1400, giving an analyst consensus of Rs 1425.

The Medanta stock forecast is set against near-term risks that make the Medanta share price prediction range wide. Investors should verify any estimate with the latest brokerage reports before using it as an investment reference. The analyst forecast will be revised after every quarterly result, so tracking changes in the Medanta stock prediction over time is more valuable than relying on any single estimate.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.

Download the Univest iOS App or Univest Android App to track the live Medanta stock prediction and share price prediction changes in real time.

Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Analyst price targets are from public brokerage reports and should be independently verified. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Medanta Stock Prediction 2026

What is the Medanta stock prediction for 2026?

Ans. The Medanta stock prediction for 2026 is based on analyst consensus from JM Financial and ICICI Securities. The consensus target is Rs 1425. All estimates may or may not be achieved.

Is the Medanta stock prediction bullish or bearish?

Ans. JM Financial has a Buy rating with target Rs 1450. ICICI Securities has a Buy rating with target Rs 1400. The Medanta stock forecast reflects genuine analyst diversity of opinion.

What is the Medanta share price prediction based on fundamentals?

Ans. The Medanta share price prediction rests on the bed addition pipeline, occupancy trend, revenue per bed and EBITDA margin maturity. Analysts tracking Medanta closely cite these as the primary drivers of the 2026 outlook.

What is the long-term Medanta stock prediction?

Ans. The long-term Medanta stock prediction assumes the company sustains its core business drivers over a multi-year horizon. The 12-month consensus of Rs 1425 is the nearest reliable anchor point.

What are the key risks to the Medanta stock prediction?

Ans. The primary risks include sector-specific headwinds, macro uncertainty, regulatory changes and competitive pressure. Every Medanta stock prediction should be read alongside its risk assumptions.

What does the Medanta stock forecast say for 2026?

Ans. JM Financial: Buy target Rs 1450. ICICI Securities: Buy target Rs 1400. These Medanta share price prediction estimates may or may not prove accurate.

Where can I track the latest Medanta stock prediction?

Ans. Track the latest Medanta stock prediction on the NSE and BSE websites and on the Univest app and screener for live price and updated analyst targets.



News
Author: Neeraj Pandey
Neeraj Pandey is a Financial Content Writer at Univest, covering Indian equity markets with a specialisation in quarterly earnings previews and analyst consensus analysis. His published work tracks Q4 FY26 results across 10+ sectors — from IT heavyweights like Infosys and TCS to PSUs like Coal India and Balmer Lawrie, and mid-caps like Neuland Laboratories, MCX, and Whirlpool of India. His writing approach is data-first: every article anchors on NSE/BSE filings, analyst consensus estimates (revenue, PAT, EBITDA margins), 52-week price context, and YoY/QoQ comparisons — giving retail investors the same structured framework institutional desks use before an earnings event. He combines SEO-optimised structure with rigorous data sourcing, ensuring each preview ranks for investor search intent while meeting SEBI editorial standards. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards.

Leave a Reply Cancel reply